This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...

The committee recommended the combo for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations based on data from the MARIPOSA trial.

A gene mutation is a permanent alteration in the DNA sequence of a gene. These changes can be as small as a single base pair or involve a large segment of DNA. Gene mutations are primarily categorized ...

A buildup of reactive oxygen species (ROS), a byproduct of many cellular processes, is associated with diseases including cancer. While ROS plays an important role in processes such as cell signaling ...

Genetic data is more readily available than ever before—but interpreting it can be a challenge. Without months of work in the laboratory, it can be tough to tell what one of the millions of ...

Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC. First-line treatment with the combination of ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday that the European Commission has approved Tagrisso (osimertinib) to treat adult patients with locally advanced, ...

How would you summarize your study for a lay audience? Our study introduces a new tool called FUSE (Functional Substitution Estimation) that helps scientists better understand how changes in genes ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...

Patients prescribed the combination therapy should be given anticoagulant prophylaxis to prevent VTE during the first 4 months of treatment. The Food and Drug Administration (FDA) has approved ...